论文部分内容阅读
急性髓系白血病(AML)大多采用传统的细胞毒药物的化学治疗,但过半数的病人会因为化疗并发症或最终复发而死亡。近年来国内外对白血病分子发病机理有了深入研究,发现有相当部分AML存在着分子信号通路中某些激酶的变异或过度表达,而针对这些活性变异激酶的小分子抑制剂得到了广泛的关注,这些小分子抑制剂能将分子信号通路中的某一酶蛋白作为靶点,影响着分子信号通路的调节控制及细胞凋亡,它们对早期的AML、复发难治的AML、以及慢性髓系白血病(CML)、骨髓增生异常综合征(MDS)等疾病都有着不容忽视的治疗效果。
Acute myeloid leukemia (AML) mostly uses traditional chemotherapy of cytotoxic drugs, but more than half of patients die of chemotherapy complications or eventual recurrence. In recent years, the pathogenesis of leukemia in vitro and in vivo has been studied in depth, and found that there is a considerable part of AML molecular signal pathway in certain kinases mutation or overexpression, and for these small kinases inhibitors of activity mutant kinase has received widespread attention , These small molecule inhibitors can target a certain enzyme protein in the molecular signaling pathway and influence the regulation and control of molecular signaling pathways and apoptosis. Their effects on early AML, relapsed-refractory AML, and chronic myeloid Leukemia (CML), myelodysplastic syndrome (MDS) and other diseases have a therapeutic effect can not be ignored.